// App-Quantinova.ai

[FRI0059] : ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) DEFINED REMISSION IS AS STRINGENT AS ACR/EULAR BOOLEAN-DEFINED REMISSION IN A CLINICAL TRIAL OF PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT

Researchers

Presenter

  • Y. Yazici

Principal Investigators

  • K.K. Gandhi

  • E. Alemao

  • D.E. Furst

Medical Centers

  • University of California at Los Angeles, Los Angeles, California, United States

  • NYU Hospital for Joint Diseases, New York, NY

Locations

  • United States

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • High sensitivity C-reactive protein

  • Albumin/creatinine

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved